| Project/Area Number |
26461957
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
川尻 成美 大阪市立大学, 大学院医学研究科, 登録医 (40597283)
大平 雅一 大阪市立大学, 大学院医学研究科, 教授 (90203926)
高島 勉 大阪市立大学, 大学院医学研究科, 講師 (80336776)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | トリプルネガティブ乳癌 / 個別化治療 / 上皮間葉転換 / E-cadherin |
|---|
| Outline of Final Research Achievements |
Triple-negative breast cancer (TNBC), a subtype of breast cancer that is estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative, has a poor prognosis. Recent research indicates that TNBC can be categorized into seven specific subcategories based on genetic expression profiles. In this study, we showed the possibility of a new therapeutic strategy for TNBC.
|
